Quick Takeaways
- Andrew Gengos has 4 issuer positions tracked on this page.
- Estimated disclosed ownership value: $4,167,438.
- Recent insider filing activity is available below.
Follow Filing Activity
Follow Andrew Gengos and return when a new Insider Trading filing appears.
This tracks SEC filing changes for this page using existing product update flows.
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
See Original Filing| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| TERN | Terns Pharmaceuticals, Inc. | Chief Financial Officer | $4,112,235 | +$96,366 | +2.4% | 14 Jan 2026 |
| LONA | Athira Pharma, Inc. | CFO and Chief Business Officer | $55,203 | 03 Sep 2024 | ||
| CYT | Cyteir Therapeutics, Inc. | Chief Business Officer | 22 Feb 2022 | |||
| TTRX | Global Health Solutions, Inc | Director | 08 Oct 2025 |
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|